Conmed upgraded to Overweight from Neutral at Piper Jaffray. Piper Jaffray analyst Matt O'Brien upgraded Conmed to Overweight from Neutral and raised his price target to $110 from $88, saying he has "foolishly" remained on the sidelines for several years due to the combination of heavy debt burden and a lack of operating margin leverage. However, O'Brien tells investors in a research note that he has traveled with management recently, and has seen the strong flow of organic new products, along with a better appreciation of the assets Conmed has added to the business, and says that he is confident despite missing a big move in the name in recent quarters, there is still a long way for the stock to go.
